• Polyrizon signed its first U.S. Clinical Trial Agreement for NASARIX (PL-14), securing a Texas allergy-focused research site as first center in planned multi-center study in seasonal allergic rhinitis.
• Trial will evaluate safety, tolerability, and efficacy versus saline spray, targeting clinical validation of a non-drug nasal barrier intended to block airborne allergens.
• No study results have been presented; readout is expected in the future once enrollment and trial execution begin.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polyrizon Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-055510), on May 13, 2026, and is solely responsible for the information contained therein.